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ABSTRACT
Objective Liver biopsy is currently the most reliable
way of evaluating liver fibrosis in patients with non-
alcoholic fatty liver disease (NAFLD). Its inherent risks
limit its widespread use. Differential liver DNA
methylation of peroxisome proliferator-activated receptor
gamma (PPARγ) gene promoter has recently been shown
to stratify patients in terms of fibrosis severity but
requires access to liver tissue. The aim of this study was
to assess whether DNA methylation of circulating DNA
could be detected in human plasma and potentially used
to stratify liver fibrosis severity in patients with NAFLD.
Design Patients with biopsy-proven NAFLD and age-
matched controls were recruited from the liver and
gastroenterology clinics at the Newcastle upon Tyne
Hospitals NHS Foundation Trust. Plasma cell-free
circulating DNA methylation of PPARγ was quantitatively
assessed by pyrosequencing. Liver DNA methylation was
quantitatively assessed by pyrosequencing NAFLD
explant tissue, subjected to laser capture microdissection
(LCM). Patients with alcoholic liver disease (ALD) were
also subjected to plasma DNA and LCM pyrosequencing.
Results 26 patients with biopsy-proven NAFLD were
included. Quantitative plasma DNA methylation of
PPARγ stratified patients into mild (Kleiner 1–2) and
severe (Kleiner 3–4) fibrosis (CpG1: 63% vs 86%,
p<0.05; CpG2: 51% vs 65% p>0.05). Hypermethylation
at the PPARγ promoter of plasma DNA correlated with
changes in hepatocellular rather than myofibroblast DNA
methylation. Similar results were demonstrated in
patients with ALD cirrhosis.
Conclusions Differential DNA methylation at the
PPARγ promoter can be detected within the pool of cell-
free DNA of human plasma. With further validation,
plasma DNA methylation of PPARγ could potentially be
used to non-invasively stratify liver fibrosis severity in
patients with NAFLD. Plasma DNA methylation
signatures reflect the molecular pathology associated
with fibrotic liver disease.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) now
comprises the majority of liver disease burden in
the Western world. In particular, the prevalence of
NAFLD is rising, in line with increasing prevalence
of obesity and insulin resistance, as lifestyles have
become increasingly sedentary and dietary patterns
have changed.1 NAFLD is a spectrum of liver
disease that includes simple steatosis, fatty infiltra-
tion plus inflammation and hepatocellular balloon-
ing degeneration (non-alcoholic steatohepatitis;
NASH), fibrosis and ultimately cirrhosis.2 Overall,
NAFLD is associated with an increased risk of both
cardiovascular disease and liver-related mortality.3
Recent studies indicate that both steatosis and
NASH may progress to advanced liver disease4–6
and that the presence and severity of fibrosis is the
key histological determinant of long-term progno-
sis;7 8 this subset of patients are more likely to
Significance of this study
What is already known on this subject?
▸ Non-alcoholic fatty liver disease (NAFLD)
accounts for the majority of liver disease
burden in the Western world.
▸ Liver biopsy remains the gold standard test to
accurately stage fibrosis in patients with
NAFLD, but it is invasive and carries risks.
▸ Differential DNA methylation of peroxisome
proliferator-activated receptor gamma (PPARγ)
has recently been shown to stratify fibrosis
severity in liver biopsies of patients with
NAFLD.
What are the new findings?
▸ Differential DNA methylation at the PPARγ
promoter can be detected within the pool of
cell-free DNA of human plasma, and may
potentially stratify patients with NAFLD into
mild versus severe fibrosis.
▸ Plasma DNA methylation signatures can be
traced back to the molecular pathology in
fibrotic liver tissue, providing a biomarker of
the underlying pathological process.
How might it impact on clinical practice in
the foreseeable future?
▸ This study demonstrates a novel, potential
plasma biomarker of liver fibrosis and could, if
validated, be used to non-invasively evaluate
liver fibrosis severity, mitigating the future need
for biopsy.
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progress to decompensated cirrhosis, portal hypertension, hepa-
tocellular carcinoma (HCC) and death without liver transplant-
ation. Indeed, NAFLD is projected to be the primary indication
for liver transplantation in many countries within a decade.9
It is imperative to accurately determine the presence of fibro-
sis in patients with NAFLD; a liver biopsy remains the gold
standard for diagnosing and staging fibrosis, but is seldom per-
formed due to perceived risk of complications. In addition, liver
biopsy is subject to sampling error, while the pathology assess-
ment of the degree of liver fibrosis and the stage of disease
often suffers from interobserver error. Together, these problems
have hampered both routine clinical care and the development
of pharmacological treatments for fibrotic liver diseases.
Non-invasive scoring systems with high negative predictive
value, such as the NAFLD fibrosis score, are used in the clinic
to exclude patients with advanced fibrotic disease.10 11
However, up to one quarter of patients cannot be classified
using this scoring system,10 and so require liver biopsy for histo-
logical clarification. Liver stiffness measurement (FibroScan/
acoustic radiation force impulse) performs well for the diagnosis
of liver fibrosis, but has a low success rate in obese patients with
NAFLD.12 Ultimately, there is an urgent and unmet need to
develop non-invasive markers that can accurately stratify fibrosis
severity in patients, reflect underlying fibrotic processes, and
could potentially be used to monitor disease progression and a
therapeutic response to emerging antifibrotic medicines.
While there is unquestionably a role for gene polymorphisms
in the progression of NASH to fibrosis there is also strong evi-
dence for the involvement of lifestyle factors (age, diet, exercise,
other comorbidities and so on).1 It is increasingly apparent that
the environmental and lifestyle experiences of an individual are
important influences on disease susceptibility and outcome.
Furthermore, there is increasing awareness that these extrinsic
experiences impact on gene expression through numerous epi-
genetic mechanisms, with the result that the phenotype and
behaviour of cells and tissues are modified in a dynamic fashion.
There is a steady accumulation of experimental and observa-
tional clinic information supporting the concept that epigenetic
processes orchestrate the behaviour of liver cells and underpin
the pathobiology of most liver diseases including NAFLD.13
DNA methylation is a fundamental epigenetic modification of
DNA that occurs at the cytosine base within a cytosine-guanine
dinucleotide (often referred to as CpG).14 A long-held biological
dogma is that CpG methylation is a stable feature of the
genome that is annotated during embryo development and
serves to repress gene expression either by inhibiting the
binding of transcription factors at gene promoters or by recruit-
ing methyl DNA binding proteins that subsequently assemble
gene transcription repression complexes.15 However, the recent
discovery of mechanisms that operate to demethylate DNA and
the development of next-generation sequencing protocols that
allow sequence-specific quantification of DNA methylation have
revealed that DNA methylation is not fixed but is highly
dynamic and is responsive to cellular and tissue microenviron-
ments.16 17 Indeed the epigenetic evolution of cancer is now a
well-established concept and can be tracked by monitoring
methylome changes during the growth and spread of a tumour
and in response to chemotherapy.18 Work in our laboratory has
shown that dynamic changes in DNA methylation are mechanis-
tically implicated in the pivotal event of fibrogenesis, the activa-
tion (or transdifferentiation) of hepatic stellate cells (HSCs) into
matrix-producing myofibroblasts.16 19 20 Additionally, we have
published observational studies using archival human NAFLD
and alcoholic liver disease (ALD) biopsy tissues to demonstrate
that differential methylation densities at a number of fibrosis-
regulating gene loci (peroxisome proliferator-activated receptor
gamma (PPARγ), PPARα, tumour growth factor beta and
platelet-derived growth factor alpha (PDGFα)) can be employed
to stratify fibrosis severity.21 22 As an example, the PPARγ is a
member of the nuclear hormone receptor family,23 involved in
lipid storage and metabolism, glucose homeostasis and adipo-
genesis.24 25 It is also a master negative regulator of HSC activa-
tion and liver fibrogenesis.19 Of relevance to the use of DNA
methylation as a potential stratification tool, the promoter
region of PPARγ undergoes methylation remodelling and
becomes hypermethylated as fibrosis severity increases in human
NASH liver biopsies.21 However, measurement of methylation
at the PPARγ promoter in these studies has relied on access to
liver tissue and hence is dependent on a biopsy.
The main aim of the present study was to ask if differential
DNA methylation at the PPARγ promoter can be detected
within the pool of cell-free DNA of human plasma and if so
then do levels of methylation at this loci correlate with fibrosis
stage in NASH.
METHODS
NAFLD cohort
Use of human tissue was approved by Newcastle and North
Tyneside Local Research Ethics (approval number H10/
H0906/41). All samples were collected and used subject to
patients’ written consent. Patients were identified from a subspe-
cialist tertiary NAFLD clinic at the Freeman Hospital, Newcastle
upon Tyne, UK. All liver samples were collected and used subject
to patient’s written consent prior to the day of surgery. Two
patients transplanted for cirrhotic NAFLD from the Freeman
Hospital, Newcastle upon Tyne, UK were included in the study.
Liver biopsies were performed as part of investigation of abnor-
mal liver function tests, or to stage disease severity, in patients
with radiological evidence of NAFLD. Patients with alternate
liver diagnoses or evidence of coexistent liver disease (haemo-
chromatosis, viral hepatitis, Wilson’s disease, α-1-antitrypsin defi-
ciency or autoimmune liver disease) were excluded. Patients who
consumed more than 20 g of alcohol per day for males or more
than 10 g per day for females were excluded. Clinical and labora-
tory data were collected from the time of liver biopsy. Relevant
clinical details such as gender, age, weight, height and average
current and previous alcohol intake (g/day) were obtained from
all patients at the time of liver biopsy. The body mass index was
calculated by the formula: weight (kg)/height2 (m2). Patients
were identified as having type 2 diabetes if they were receiving
dietary, oral hypoglycaemic drug or insulin treatment for dia-
betes, or had fasting blood glucose >7.0 mmol/L or glucose
>11.1 mmol/L following an oral glucose tolerance test. Blood
tests taken at the time of liver biopsy were used to calculate the
NAFLD fibrosis score as previously described.26
ALD cohort
Use of human tissue was approved by Newcastle and North
Tyneside Local Research Ethics (approval number H10/
H0906/41). Blood was collected at the time of patient identifi-
cation in the liver clinics at the Freeman Hospital, Newcastle
upon Tyne, UK. All liver samples were collected and used
subject to patient’s written consent prior to the day of surgery.
Four patients transplanted for cirrhotic ALD from the Freeman
Hospital, Newcastle upon Tyne, UK were included in the study.
A diagnosis of ALD was made with abnormal serum transami-
nases, the presence of excess alcohol intake (>60 g/day for
males, >40 g/day for females) and the exclusion of other
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diagnoses such as viral hepatitis (HBV, HCV and HIV), heredi-
tary hemochromatosis, Wilson’s disease, autoimmune hepatitis,
α1 antitrypsin deficiency and drug-induced liver injury.
Histological assessment
Percutaneous liver biopsies were performed using a Menghini
needle or an 18G BioPince liver biopsy system (Medical Devices
Technologies, Gainesville, Florida, USA). Liver biopsies were all
>15 mm in length and were interpreted by an experienced
hepatopathologist (DT). Histological scoring was performed
according to the NASH Clinical Research Network criteria.27
The NAFLD activity score was graded from 0 to 8 including
scores for steatosis (0–3), lobular inflammation (0–3) and hepa-
tocellular ballooning (0–2). Fibrosis was staged from 0 to 4.
Control cohort
Use of human tissue was approved by Newcastle and North
Tyneside Local Research Ethics (approval number H10/
H0906/41). All samples were collected and used subject to
patients’ written consent. Age-matched controls were identified
from the general gastroenterology clinics and endoscopy services
at the Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Patients had no signs or symptoms of liver disease, and no
history of chronic illnesses.
DNA methylation analysis
DNA was extracted from 200 μL of plasma using the QIAamp
DNA blood mini kit and was bisulfite treated with EZ DNA
Methylation Gold Kit (Zymo, USA) according to the manufac-
turer’s protocol. The bisulfite-treated DNA was eluted in 10 μL
elution buffer.
Similarly, DNA was extracted from laser capture microdis-
sected tissue (PALM MicroBeam, Zeiss, Germany) using the
QIAamp DNA micro kit according to the manufacturer’s proto-
col and bisulfite treated as above. A detailed method is available
in online supplementary documents.
Pyrosequencing analysis
Methylation of specific cytosines within CpG dinucleotides was
quantified by pyrosequencing using a Pyromark Q96 MD
(Qiagen) instrument. PCR and sequencing primers were
obtained from a custom-designed assay for PPARγ (Eurofins
Genomics, Luxembourg) as previously described.21 Ten microli-
tres of biotin-labelled PCR product was used in each well and
combined by streptavidin-coated sepharose beads, washed in
70% ethanol, denatured in 0.01% sodium azide and washed in
a wash buffer (Qiagen, PyroMark Wash Buffer, 979008).
Sequencing primers were annealed to DNA product at 80°C.
Samples were run in duplicate. Assay efficiency was validated by
unmethylated and methylated DNA (Qiagen, EpiTect PCR
Control DNA Set, 59695). CpG methylation data were analysed
by Pyro Q-CpG software 1.0.6.
Statistical analysis
All statistical analyses were performed using SPSS software
V.21.0 (SPSS, Chicago, USA). Continuous normally distributed
variables were represented as mean±SD. Categorical and non-
normal variables were summarised as median and range. χ2 test
or Fisher’s exact test was used to determine the distribution of
categorical variables between groups. To compare the means of
normally distributed variables between groups, the Student’s
t test was performed. To determine differences between groups
for continuous non-normally distributed variables, medians were
compared using the Mann–Whitney U test. The diagnostic
performance of non-invasive tests was assessed by receiver oper-
ating characteristic (ROC) curves. The area under the ROC
(AUROC) was used as an index to compare the accuracy of tests.
The cut-off for diagnosis of advanced fibrosis was taken from the
point of maximum combined sensitivity and specificity. The sen-
sitivity and specificity for relevant cut-offs were also displayed.
RESULTS
A total of 26 patients with NAFLD were identified who had a
liver biopsy to investigate abnormal liver enzymes or to stage
fibrosis in those with imaging evidence of steatosis. Fourteen
had mild fibrosis (Kleiner 0–2) and 12 had severe (Kleiner 3–4)
fibrosis. The demographic and laboratory characteristics of all
patients are shown in table 1.
Plasma DNA methylation of PPARγ gene promoter increases
with fibrosis severity in NAFLD
In studies analysing DNA methylation in liver tissue, we have
previously shown that differential DNA methylation at particular
CpG dinucleotides within the human PPARγ gene promoter can
be used to stratify fibrosis severity in patients with NAFLD.21
Quantitatively, in mild fibrosis, CpG methylation density was
measured at >70% rising to >80% in severe fibrosis, at the two
loci examined. In light of these results, it was logical to analyse
the quantitative methylation of the same gene promoter region
in PPARγ in plasma cell-free circulating DNA. To this end, we
collected blood from patients and healthy controls, then isolated
cell-free DNA (see online supplementary figure S1A). Using
tested and optimised pyrosequencing primers (see online
supplementary figure S1B), the amount of DNA methylation at
two specific CpG loci within PPARγ promoter was quantitatively
measured in all samples (figure 1A–C). We found increases in
DNA methylation at both CpG loci in patients with severe
versus mild fibrosis and controls (figure 1B, C), reaching high
statistical significance between the patients with mild and severe
NAFLD in the first CpG loci (figure 1B).
Next, we wanted to assess whether increases in plasma DNA
methylation at PPARγ gene promoter were fibrosis related or
aetiology related. We therefore analysed 13 patients with clinical
evidence of cirrhosis due to excessive alcohol consumption
(ALD) and compared them with healthy controls, as it was not
possible to find patients who had mild ALD. Clinical character-
istics of the ALD cohort are shown in table 2. Remarkably, we
Table 1 Characteristics of the NAFLD cohort
Clinical characteristic
Mild NAFLD
fibrosis (F0–2)
n=14
Advanced NAFLD
fibrosis (F3–F4)
n=12 p Value
Age (years) 57±7 59±12 0.56*
Gender (male) 29% 67% 0.052†
BMI (kg/m2) 36.0±5.5 36.0±7.3 0.996*
Diabetes 50% 67% 0.39†
ALT (IU/L) 55±37 62±19 0.55*
AST (IU/L) 39±13 53±12 0.01*
ALB (g/L) 46±3 45±4 0.37*
Platelets (×109/L) 234±54 223±70 0.67*
AST/ALT ratio 0.80±0.23 0.91±0.27 0.29*
NAFLD fibrosis score −0.87±0.95 −0.34±1.14 0.22*
Data expressed as mean±SD or median (range).
*Student’s t test.
†χ2 test.
ALB, albumin; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body
mass index; NAFLD, non-alcoholic fatty liver disease.
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again found evidence of fibrosis-associated hypermethylation at
both CpG loci within the PPARγ promoter in patients with cir-
rhotic ALD when compared with healthy controls (figure 1D, E).
These data suggest that PPARγ promoter hypermethylation is
unlikely to be limited to a particular aetiology of liver disease
but is instead closely associated with disease progression and
development of fibrosis.
Finally, we analysed plasma DNA methylation at a specific
loci at PDGFα gene; we chose PDGF as it is a well-established
profibrotic gene, at which we have previously shown differential
DNA methylation.22 In NAFLD liver biopsies, a particular CpG
loci undergoes remodelling and becomes hypomethylated with
increasing fibrosis severity.22 Remarkably, we found decreases in
plasma DNA methylation at the same CpG loci in patients with
NAFLD with severe versus mild fibrosis; similar decreases were
found in patients with cirrhotic ALD versus controls (see online
supplementary figure S2).
Plasma DNA methylation of PPARγ as an independent
predictor of fibrosis severity in NAFLD
To ascertain whether plasma PPARγ DNA methylation level at
locus CpG1 independently predicted fibrosis severity, we per-
formed a multivariate logistic regression analysis. PPARγ DNA
methylation level and clinical biochemistry indices found to be
significant on univariate analysis (AST) were included to control
for possible confounders of the association between fibrosis
severity and plasma PPARγ DNA methylation level. PPARγ
remained statistically significant (p=0.01), while AST lost signifi-
cance (p=0.095). To assess the clinical applicability of this test
we assessed its diagnostic performance for advanced NAFLD
fibrosis (Kleiner 3–4) using the AUROC analysis (figure 2A). The
AUROC was 0.91, which was significantly higher than a chance
assignment (asymptotic significance p=0.000). The threshold
PPARγ CpG1 methylation value of 81% was the optimum
cut-off to differentiate mild from advanced fibrosis. This score
compared favourably with the NAFLD fibrosis score, a
well-validated, widely used non-invasive fibrosis score (figure 2).
The sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) for PPARγ CpG1 methylation
and the NAFLD fibrosis score are shown in figure 2B.
Hypermethylation at the PPARγ promoter of plasma DNA
correlates with changes in hepatocellular rather than
myofibroblast DNA methylation
We were next interested to determine if the degree of PPARγ
promoter hypermethylation detected in plasma DNA reflected
cellular changes in the diseased liver. In particular, we wanted to
Figure 1 (A) Schematic
representation of peroxisome
proliferator-activated receptor gamma
(PPARγ) gene promoter showing the
positions of the differentially
methylated CpG 1 and 2. (B and C)
Plasma DNA methylation at (B) CpG1
and (C) CpG2 dinucleotide within the
human PPARγ gene promoter from
patients with mild or severe
non-alcoholic fatty liver disease and
controls as determined by
pyrosequencing. (D and E) Plasma
DNA methylation at (D) CpG1 and (E)
CpG2 dinucleotide within the human
PPARγ gene promoter from patients
with cirrhotic alcoholic liver disease
(ALD) and controls as determined by
pyrosequencing. DNA methylation is
quantitatively measured as expressed
as a percentage. Error bars represent
mean values±SEM. *p<0.05,
**p<0.01, ***p<0.001 and
****p<0.0001.
Table 2 Clinical characteristics of ALD cohort
Clinical characteristic Cirrhotic ALD n=13
Age (years) 57±6
Gender (%male) 85%
ALT (IU/L) 34±14
AST (IU/L) 37±6
ALB (g/L) 39±6
Platelets (×109/L) 136±61
ALD, alcoholic liver disease.
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exploit the technology of laser capture microdissection (LCM)
to separate myofibroblast-enriched fibrotic tissue from surround-
ing non-fibrotic hepatic parenchyma in advanced NASH liver
explants. NAFLD explants were characterised by an expert
histopathologist (DT) (figure 3A), then LCM was used to cut
out either hepatocyte-rich regions (figure 3B, left panel) or
myofibroblast-rich scar regions (figure 3B, right panel). Once
again, the DNA methylation status of the two CpG loci within
PPARγ promoter was determined by pyrosequencing using
genomic DNA isolated from LCM-obtained tissues (figure 3C,
D). Both CpG loci were hypermethylated in the hepatic paren-
chyma compared with areas enriched for myofibroblasts
(figure 3C, D). The average DNA methylation percentages were
79 and 78 for CpG1 and CpG2, respectively, in the captured
hepatocyte nodules compared with 63 and 61 in fibrotic tissue.
When compared with similar measurements on parenchymal
tissue from non-diseased liver tissue (76% and 70% for CpG1
and CpG2, respectively, online supplementary figure S3A), and
control peripheral blood mononuclear cells (PBMCs) (68% and
63% for CpG1 and CpG2, respectively, online supplementary
figure S3B), our LCM-pyrosequencing data suggest that PPARγ
promoter hypermethylation detected in plasma more closely
correlates with methylation changes in hepatocytes than in myo-
fibroblasts or PBMCs. To corroborate this finding we carried
out similar LCM-pyrosequencing assays using ALD explant
tissues (representative images shown in figure 4A), again using
LCM to isolate hepatocyte-enriched (figure 4B, left panel) or
myofibroblast-enriched regions (figure 4B, right panel). As with
NAFLD, we discovered relative hypermethylation of the CpG1
and CpG2 sites in the PPARγ promoter for hepatocyte-enriched
versus myofibroblast-enriched tissues (figure 4C, D). Hence,
irrespective of the cause of steatotic liver disease, progression to
the advanced stage is associated with PPARγ promoter hyper-
methylation in DNA isolated from plasma and hepatocyte-
enriched regenerative nodules.
DISCUSSION
Non-invasive or minimal-invasive biomarkers of disease progres-
sion are sorely needed in light of the currently rising liver
disease burden. In particular, NAFLD is increasing in incidence,
and is projected to be the primary indication for liver trans-
plantation by 2020.9 Recently, the presence of fibrosis has been
shown to be the key histological determinant of long-term prog-
nosis.7 8 Thus, an accurate determination of the degree of fibro-
sis is absolutely critical to allow effective management of this
disease. The NAFLD fibrosis score is currently widely adopted
in routine practice to help rationalise liver biopsy use, but for
many patients fails to provide a satisfactory quantitative measure
of their disease progression without referral to a liver biopsy.10
Dynamic biomarkers of disease progression that can be detected
in patient blood offer the advantage of minimal-invasive regular
monitoring of disease progression and if prognostic would be
extremely helpful for clinical management and the design of
clinical trials in NASH and other major forms of chronic liver
disease.
Here we show in NAFLD and ALD that sequence-specific
quantification of methylation densities at so-called differential
DNA methylation regions (DMRs) may be employed to stratify
patients according to their disease severity. Specifically, using
two CpG sequences previously identified as DMRs in the
PPARγ promoter we have shown that hypermethylation at these
sequences correlates with advanced fibrosis/cirrhosis. This
finding correlates with our previous data demonstrating that
hypermethylation at the same PPARγ promoter DMRs in liver
biopsy tissues can be used to identify patients who had pro-
gressed to Kleiner grade 3–4.21 While our study used only a
relatively low number of patient samples (26 NAFLD and 13
ALD), the fact that PPARγ promoter hypermethylation corre-
lated with disease progression across two distinct disease aetiolo-
gies is encouraging and supportive of further studies on the
diagnostic and prognostic utility of PPARγ DMRs and indeed
other genomic DMRs. Equally, our demonstration of differential
plasma DNA methylation in two distinct and opposite gene
DMRs further strengthens our study.
An interesting question is the cellular source of the hyper-
methylated PPARγ DNA in plasma of liver disease patients.
Hepatocyte damage and death are characteristic components of
the pathobiology of NASH and ALD and would be expected to
result in substantial leakage of cell-free DNA into the circula-
tion. Moreover, a recent paper has reported that the liver contri-
butes significantly to the pool of DNA that circulates freely in
the plasma.28 Given the similar degree of PPARγ hypermethyla-
tion at CpG1 and CpG2 in plasma and hepatocyte-rich tissue
captured by LCM it is tempting to speculate that dying hepato-
cytes represent the cellular source of hypermethylated plasma
DNA. However, at the time of writing we lack sufficient direct
evidence to support this idea.
An unexpected finding from our LCM-pyrosequencing studies
was a higher density of methylation at the CpG1 and CpG2
PPARγ promoter DMRs in hepatocyte-rich tissue compared with
myofibroblast-rich fibrotic tissue, and this is observed in both
NASH and ALD livers. There is strong association of PPARγ
expression with the quiescent non-fibrogenic phenotype of HSC
and a need to repress its transcription in order for the cells to
Figure 2 (A) Receiver operating characteristic (ROC) curves for the
non-invasive diagnosis of advanced fibrosis (Kleiner fibrosis stage 3–4)
using quantitative DNA methylation data for peroxisome
proliferator-activated receptor gamma (PPARγ) CpG1 as compared with
non-alcoholic fatty liver disease (NAFLD) fibrosis score. (B) A
comparison of the performance of each test for the stratification of
mild versus advanced fibrosis in 26 patients with non-alcoholic fatty
liver disease (non-alcoholic steatohepatitis). AUROC, area under the
ROC.
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Figure 3 (A) Representative images
of explanted non-alcoholic fatty liver
disease (NAFLD) liver tissue stained
with Sirius red and α-smooth muscle
actin (αSMA). Blue arrow within Sirius
red picture points to hepatocytes,
whereas brown arrow within
αSMA-stained section shows
myofibroblasts in the scar region.
Photomicrographs were taken at 10
times magnification. (B) Explanted
NAFLD liver tissue was subjected to
laser capture microdissection (LCM);
areas of hepatocytes were separated
from myofibroblast-enriched areas.
H&E-stained tissue prior to and after
LCM. (C and D) DNA methylation
density of (C) CpG1 and (D) CpG2
dinucleotide within the human
peroxisome proliferator-activated
receptor gamma (PPARγ) gene
promoter as determined by
pyrosequencing in LCM material from
NAFLD. DNA methylation is
quantitatively measured and expressed
as a percentage. Error bars represent
mean values±SEM *p<0.05 and
**p<0.01..
Figure 4 (A) Representative images
of explanted alcoholic liver disease
(ALD) tissue stained with Masson’s
trichrome, Sirius red and α-smooth
muscle actin (αSMA). Blue arrows
point to hepatocytes, whereas brown
arrows point to the myofibroblasts in
the αSMA stained scar region.
Photomicrographs were taken at 10
times magnification. (B) H&E stained
explanted ALD liver tissue was
subjected to laser capture
microdissection (LCM); areas of
hepatocytes were separated from
myofibroblast-enriched areas. Images
show the tissue prior to and after
LCM. (C and D) DNA methylation
density of (C) CpG1 and (D) CpG2
dinucleotide within the human
peroxisome proliferator-activated
receptor gamma (PPARγ) gene
promoter as determined by
pyrosequencing in LCM material from
ALD. The positions of the differentially
methylated CpGs are shown in the
schematic drawing above the graphs.
Differences are expressed as a
percentage of DNA methylation. Error
bars represent mean values±SEM.
****p<0.0001.
6 Hardy T, et al. Gut 2016;0:1–8. doi:10.1136/gutjnl-2016-311526
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adopt a myofibroblast phenotype.29 30 We have previously
shown that the methyl-CpG binding protein MeCP2 brings
about this repression of PPARγ transcription at least in part by
associating with methylated regions of the upstream promoter
where it recruits chromatin remodelling factors.19 Hence, a
higher degree of methylation at the PPARγ promoter would be
expected to be a feature of fibrotic tissue in advanced liver
disease. However, our comparison of non-fibrotic
hepatocyte-rich tissue with fibrotic myofibroblast-rich tissue sug-
gests that DMRs in the PPARγ promoter are more highly methy-
lated in hepatocytes. Noteworthy is a recent cell-specific
knockout study reporting that hepatocyte PPARγ1 mRNA is
highly suppressed after experimental induction of liver fibrosis
in mice.31 Experimentally, the loss of PPARγ expression in hepa-
tocytes has been implicated as a signal for HSC preactivation
and accelerated fibrogenesis32; such a process may constitute an
important cross-talk mechanism between hepatocytes and HSCs
that drives disease progression to fibrosis and cirrhosis. PPARγ
has also been shown to have a regulatory role in hepatic regener-
ation. Mice with hepatocyte-targeted genetic deletion of PPARγ
display impaired regeneration within the setting of diet-induced
steatosis.33 Thus, hypermethylation of PPARγ in hepatocytes
could also reflect impaired regeneration, a major characteristic of
advanced liver disease and a driver of fibrosis.34 35
There are a number of limitations with the current study.
Clearly, the sample size is relatively small, with no independent
validation within a separate cohort. Further, our method neces-
sitates the use of prospectively collected fresh plasma samples,
precluding the immediate use of archived plasma samples from
existing cohorts at other centres. There is no data on the prog-
nosis of patients enrolled in the study, and no longitudinal mea-
surements, especially from interventional trials. Finally, the data
does not suggest superiority to existing fibrosis biomarkers,
although it performed favourably to the NAFLD fibrosis score
in this cohort. However, given the ability to detect significant
differential plasma DNA methylation in two separate gene
DMRs in this small cohort of patients, patients with NAFLD
fibrosis and patients with cirrhotic ALD, further work is war-
ranted to validate these findings in a large cohort of patients
with NAFLD, ALD and other fibrotic liver diseases.
In light of the limitations in the present study, there are clear
directions for further research. First, a validation of the findings
in a second independent cohort is required. Second, analysis of
patients from an interventional trial with paired biopsies could
reveal whether pathway-directed interventions (eg, the PPARα/δ
agonist) alter the diagnostic performance of this marker. What
we are at present unable to know is the degree to which DNA
methylation at PPARγ and other genes carrying DMRs is chan-
ging during the disease course in an individual. Thus, the diag-
nostic relevance and the prognostic value of the biomarker
should be assessed. Prediction of disease progression, during
long-term follow-up, for early NAFLD stages using the novel
technique should be evaluated. Furthermore, our knowledge of
HCC-specific epigenomic signatures and its effect on the methy-
lation pattern of PPARγ, when coexisting with NAFLD, should
be assessed in future studies. Finally, a key question would be
whether PPARγ hypermethylation is a preset feature of patients
who are susceptible to disease progression or if it is a more
dynamic modification that develops with disease.
In summary, our findings suggest that plasma DNA can be
detected and potentially used to non-invasively stratify fibrosis
risk in NAFLD according to methylation levels at DMRs within
the PPARγ gene promoter. With validation, this blood-based
biomarker could become an important contributory clinical tool
alongside other epigenetic, genetic and biochemical biomarkers,
mitigating the future need for biopsy to evaluate fibrosis.
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